News | May 05, 2025
Biocon Biologics secures strong market coverage for Yesintek in US
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Investment demonstrates confidence in America’s commitment to science and innovation
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Delivers robust earnings performance, successfully navigating a dynamic environment
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Subscribe To Our Newsletter & Stay Updated
